Salivary Soluble CD44: A Molecular Marker for HNSCC

描述（由申请人提供）： 头颈部鳞状细胞癌（HNSCC）占全球约500，000例癌症事件。HNSCC的治疗，手术，放疗和化疗的组合，通常会导致显着的发病率和大量的医疗保健费用。消除最初的肿瘤提供了最好的治愈机会，但我们只有50%的成功率。治疗失败最常见的原因是原发部位或颈部复发，而很少是远处转移。当早期发现初始或复发肿瘤时，治疗效果更好。不幸的是，大多数HNSCC是在后期发现的。一种能够在早期阶段检测新癌症和复发的HNSCC标志物将是有用的。CD44可能是其他组织中恶性肿瘤的分子标志物，并且在体液中以可溶性形式（solCD44）可检测到。我们的初步数据表明，与对照相比，在HNSCC肿瘤患者的唾液中solCD44增加。在这项研究中，我们将检查新诊断的HNSCC患者和对照以及复发或第二原发的HNSCC患者中solCD44的表达。我们将使用solCD44 ELISA测试和蛋白质测定来评估HNSCC患者唾液中solCD44的表达（目的1）。我们将这些与年龄，性别，种族，社会经济地位，烟草和酒精使用相匹配的对照组中的sol CD44水平进行比较。我们将使用相同的测定来评估复发性或第二原发性HNSCC患者中sol ⑶ 44的表达，所述患者与先前治疗、初始阶段、烟草和酒精使用相匹配（目的2）。这些研究的结果将确定soICD 44 ELISA检测作为HNSCC筛查检测的有效性。

DESCRIPTION (provided by applicant): Head and neck squamous cell carcinoma (HNSCC) accounts for approximately 500,000 incident cancers worldwide. The treatment of HNSCC, combinations of surgery, radiation and chemotherapy, often result in significant morbidity and substantial healthcare costs. Elimination of the initial tumor offers the best chance of cure, yet we succeed only 50 percent of the time. Therapy fails most often due to recurrence at the primary site or in the neck, and less often from distant metastases. When initial or recurrent tumors are identified early, treatment outcome is better. Unfortunately the majority of HNSCC are identified in later stage. A marker for HNSCC that is able to detect new cancers and recurrences in early stages would be useful. CD44 may be a molecular marker of malignancy in other tissues and is detectable in body fluids in soluble form (solCD44). Our preliminary data suggest that solCD44 is increased in the saliva of HNSCC tumor patients compared to controls. In this study we will examine the expression of solCD44 in both newly diagnosed HNSCC patients and controls and in HNSCC patients with recurrence or second primaries. We will use a solCD44 ELISA test and a protein assay to evaluate the expression of solCD44 in HNSCC patient's saliva (aim 1). We will compare these to sol CD44 levels in controls that are matched for age, sex, race, socioeconomic status, tobacco and alcohol use. We will use the same assays to evaluate the expression of solCD44 in patients with recurrent or second primary HNSCC matching for previous treatment, original stage, tobacco and alcohol use (aim 2). The results of these studies will determine the validity of soICD44 ELISA test as a screening test for HNSCC.